These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 37182129)

  • 1. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
    Pan H; Lu W; Zhang M; Liu C
    Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
    Wang K; Yu M; Zhang Z; Yin R; Chen Q; Zhao X; Yu H
    Transl Cancer Res; 2023 May; 12(5):1270-1289. PubMed ID: 37304554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Jun; 36(6):e24409. PubMed ID: 35441741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of m
    Wu J; Hou C; Wang Y; Wang Z; Li P; Wang Z
    Int J Genomics; 2021; 2021():3803724. PubMed ID: 34631874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
    He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging diverse cell-death patterns to predict the prognosis, immunotherapy and drug sensitivity of clear cell renal cell carcinoma.
    Zhang X; Zhang M; Song L; Wang S; Wei X; Shao W; Song N
    Sci Rep; 2023 Nov; 13(1):20266. PubMed ID: 37985807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
    Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
    Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-validated immune infiltration-related gene model predicts prognosis and immunotherapy sensitivity in HNSCC.
    Ding Y; Chu L; Cao Q; Lei H; Li X; Zhuang Q
    BMC Cancer; 2023 Jan; 23(1):45. PubMed ID: 36639648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal enhanced CT images reveal the tandem mechanism between tumor cells and immunocytes based on bulk/single-cell RNA sequencing.
    Liang H; Wu K; Wu R; Huang K; Deng Z; Chen H
    Funct Integr Genomics; 2023 Mar; 23(2):88. PubMed ID: 36933049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma.
    Zhang L; Di L; Liu J; Lei X; Gu M; Zhang W; Wang Y
    Front Genet; 2023; 14():1039813. PubMed ID: 36755568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.
    Wu X; Xie W; Gong B; Fu B; Chen W; Zhou L; Luo L
    Front Oncol; 2023; 13():1162846. PubMed ID: 38023248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
    Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A promising natural killer cell-based model and a nomogram for the prognostic prediction of clear-cell renal cell carcinoma.
    Yao Q; Zhang X; Wang Y; Wang C; Chen J; Chen D
    Eur J Med Res; 2024 Jan; 29(1):73. PubMed ID: 38268058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma.
    Peng L; Liang J; Wang Q; Chen G
    Front Genet; 2022; 13():798846. PubMed ID: 35656315
    [No Abstract]   [Full Text] [Related]  

  • 18. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
    Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
    BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.